It Seems AMARILLO BIOSCIENCES INCORPORATED (OTCMKTS:AMAR) Will Go Up. Just Reported Less Shorted Shares

July 26, 2017 - By Ellis Scott

The stock of AMARILLO BIOSCIENCES INCORPORATED (OTCMKTS:AMAR) registered a decrease of 77.42% in short interest. AMAR’s total short interest was 700 shares in July as published by FINRA. Its down 77.42% from 3,100 shares, reported previously. With 1,900 shares average volume, it will take short sellers 0 days to cover their AMAR’s short positions.

It closed at $0.29 lastly. It is down 0.00% since July 26, 2016 and is . It has underperformed by 16.70% the S&P500.

Amarillo Biosciences, Inc. is engaged in the business of biopharmaceutical research and development. The company has market cap of $7.04 million. The Firm develops biologics for the treatment of human and animal diseases. It currently has negative earnings. The Company’s focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form.

More important recent Amarillo Biosciences Inc (OTCMKTS:AMAR) news were published by: Medgadget.com which released: “Hepatitis C Pipeline Drugs and Therapeutics Market 2017” on July 19, 2017, also Prnewswire.com published article titled: “2016 Pipeline of Hepatitis C Market Covering 84 Companies”, Marketwatch.com published: “2016 Thrombocytopenia Pipeline Global Market Review Report” on June 16, 2016. More interesting news about Amarillo Biosciences Inc (OTCMKTS:AMAR) was released by: Marketwatch.com and their article: “1.60” with publication date: February 24, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.